860 related articles for article (PubMed ID: 22129252)
1. Interleukin-2 and regulatory T cells in graft-versus-host disease.
Koreth J; Matsuoka K; Kim HT; McDonough SM; Bindra B; Alyea EP; Armand P; Cutler C; Ho VT; Treister NS; Bienfang DC; Prasad S; Tzachanis D; Joyce RM; Avigan DE; Antin JH; Ritz J; Soiffer RJ
N Engl J Med; 2011 Dec; 365(22):2055-66. PubMed ID: 22129252
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.
Koreth J; Kim HT; Jones KT; Lange PB; Reynolds CG; Chammas MJ; Dusenbury K; Whangbo J; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Chen YB; Avigan D; Blazar BR; Antin JH; Ritz J; Soiffer RJ
Blood; 2016 Jul; 128(1):130-7. PubMed ID: 27073224
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.
Belizaire R; Kim HT; Poryanda SJ; Mirkovic NV; Hipolito E; Savage WJ; Reynolds CG; Fields MJ; Whangbo J; Kubo T; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Blazar BR; Antin JH; Ritz J; Soiffer RJ; Koreth J
Blood Adv; 2019 Apr; 3(7):969-979. PubMed ID: 30936057
[TBL] [Abstract][Full Text] [Related]
4. Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease.
Donato V; Kim HT; Stowe P; Reynolds CG; Ritz J; Koreth J; Whangbo JS
Front Immunol; 2022; 13():954966. PubMed ID: 36189229
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.
Saadoun D; Rosenzwajg M; Joly F; Six A; Carrat F; Thibault V; Sene D; Cacoub P; Klatzmann D
N Engl J Med; 2011 Dec; 365(22):2067-77. PubMed ID: 22129253
[TBL] [Abstract][Full Text] [Related]
6. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.
Matsuoka K; Koreth J; Kim HT; Bascug G; McDonough S; Kawano Y; Murase K; Cutler C; Ho VT; Alyea EP; Armand P; Blazar BR; Antin JH; Soiffer RJ; Ritz J
Sci Transl Med; 2013 Apr; 5(179):179ra43. PubMed ID: 23552371
[TBL] [Abstract][Full Text] [Related]
7. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.
Whangbo JS; Kim HT; Mirkovic N; Leonard L; Poryanda S; Silverstein S; Kim S; Reynolds CG; Rai SC; Verrill K; Lee MA; Margossian S; Duncan C; Lehmann L; Huang J; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Blazar BR; Antin JH; Soiffer RJ; Ritz J; Koreth J
Blood Adv; 2019 Sep; 3(17):2550-2561. PubMed ID: 31471324
[TBL] [Abstract][Full Text] [Related]
8. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
[TBL] [Abstract][Full Text] [Related]
9. A glucocorticoid amplifies IL-2-induced selective expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft-versus-host disease after allogeneic lymphocyte transplantation.
Xie Y; Wu M; Song R; Ma J; Shi Y; Qin W; Jin Y
Acta Biochim Biophys Sin (Shanghai); 2009 Sep; 41(9):781-91. PubMed ID: 19727527
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.
Whangbo JS; Nikiforow S; Kim HT; Wahl J; Reynolds CG; Rai SC; Kim S; Burden A; Alho AC; Lacerda JF; Alyea EP; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Ritz J; Koreth J
Blood Adv; 2022 Nov; 6(21):5786-5796. PubMed ID: 35475885
[TBL] [Abstract][Full Text] [Related]
11. Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation.
Zorn E; Mohseni M; Kim H; Porcheray F; Lynch A; Bellucci R; Canning C; Alyea EP; Soiffer RJ; Ritz J
Biol Blood Marrow Transplant; 2009 Mar; 15(3):382-8. PubMed ID: 19203731
[TBL] [Abstract][Full Text] [Related]
12. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease.
Magenau JM; Qin X; Tawara I; Rogers CE; Kitko C; Schlough M; Bickley D; Braun TM; Jang PS; Lowler KP; Jones DM; Choi SW; Reddy P; Mineishi S; Levine JE; Ferrara JL; Paczesny S
Biol Blood Marrow Transplant; 2010 Jul; 16(7):907-14. PubMed ID: 20302964
[TBL] [Abstract][Full Text] [Related]
13. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation.
Wolf D; Wolf AM; Fong D; Rumpold H; Strasak A; Clausen J; Nachbaur D
Transplantation; 2007 Apr; 83(8):1107-13. PubMed ID: 17452902
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.
Shin HJ; Baker J; Leveson-Gower DB; Smith AT; Sega EI; Negrin RS
Blood; 2011 Aug; 118(8):2342-50. PubMed ID: 21734238
[TBL] [Abstract][Full Text] [Related]
15. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.
Nikiforow S; Kim HT; Daley H; Reynolds C; Jones KT; Armand P; Ho VT; Alyea EP; Cutler CS; Ritz J; Antin JH; Soiffer RJ; Koreth J
Haematologica; 2016 Oct; 101(10):1251-1259. PubMed ID: 27354021
[TBL] [Abstract][Full Text] [Related]
17. TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment.
Pierini A; Strober W; Moffett C; Baker J; Nishikii H; Alvarez M; Pan Y; Schneidawind D; Meyer E; Negrin RS
Blood; 2016 Aug; 128(6):866-71. PubMed ID: 27365424
[TBL] [Abstract][Full Text] [Related]
18. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.
Pillai AB; George TI; Dutt S; Strober S
Blood; 2009 Apr; 113(18):4458-67. PubMed ID: 19221040
[TBL] [Abstract][Full Text] [Related]
19. Naive and Stem Cell Memory T Cell Subset Recovery Reveals Opposing Reconstitution Patterns in CD4 and CD8 T Cells in Chronic Graft vs. Host Disease.
Soares MV; Azevedo RI; Ferreira IA; Bucar S; Ribeiro AC; Vieira A; Pereira PNG; Ribeiro RM; Ligeiro D; Alho AC; Soares AS; Camacho N; Martins C; Lourenço F; Moreno R; Ritz J; Lacerda JF
Front Immunol; 2019; 10():334. PubMed ID: 30894856
[TBL] [Abstract][Full Text] [Related]
20. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
Giorgini A; Noble A
J Leukoc Biol; 2007 Nov; 82(5):1053-61. PubMed ID: 17684039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]